Inhibrx Inc. (INBX): Price and Financial Metrics


Inhibrx Inc. (INBX): $28.82

-0.18 (-0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INBX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

INBX POWR Grades

  • INBX scores best on the Sentiment dimension, with a Sentiment rank ahead of 51.29% of US stocks.
  • The strongest trend for INBX is in Growth, which has been heading down over the past 179 days.
  • INBX's current lowest rank is in the Stability metric (where it is better than 4.64% of US stocks).

INBX Stock Summary

  • With a price/sales ratio of 264.56, INHIBRX INC has a higher such ratio than 98.78% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 16.84 for INHIBRX INC; that's greater than it is for 97.23% of US stocks.
  • As for revenue growth, note that INBX's revenue has grown -33.24% over the past 12 months; that beats the revenue growth of just 5.8% of US companies in our set.
  • Stocks that are quantitatively similar to INBX, based on their financial statements, market capitalization, and price volatility, are NTLA, CRSP, PTGX, RNA, and RLAY.
  • Visit INBX's SEC page to see the company's official filings. To visit the company's web site, go to www.inhibrx.com.

INBX Valuation Summary

  • In comparison to the median Healthcare stock, INBX's price/sales ratio is 5664.58% higher, now standing at 276.7.
  • Over the past 28 months, INBX's price/earnings ratio has gone down 0.6.

Below are key valuation metrics over time for INBX.

Stock Date P/S P/B P/E EV/EBIT
INBX 2022-11-25 276.7 -37.7 -10.5 -12.0
INBX 2022-11-23 268.6 -36.6 -10.2 -11.6
INBX 2022-11-22 273.7 -37.3 -10.4 -11.8
INBX 2022-11-21 276.3 -37.6 -10.5 -11.9
INBX 2022-11-18 264.2 -36.0 -10.0 -11.4
INBX 2022-11-17 266.4 -36.3 -10.1 -11.5

INBX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INBX has a Quality Grade of C, ranking ahead of 34.19% of graded US stocks.
  • INBX's asset turnover comes in at 0.076 -- ranking 283rd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows INBX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.076 1 -2.381

INBX Price Target

For more insight on analysts targets of INBX, see our INBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $40.50 Average Broker Recommendation 1.4 (Strong Buy)

INBX Stock Price Chart Interactive Chart >

Price chart for INBX

INBX Price/Volume Stats

Current price $28.82 52-week high $45.99
Prev. close $29.00 52-week low $7.67
Day low $28.63 Volume 202,800
Day high $29.69 Avg. volume 485,236
50-day MA $27.77 Dividend yield N/A
200-day MA $20.24 Market Cap 1.26B

Inhibrx Inc. (INBX) Company Bio


Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.


INBX Latest News Stream


Event/Time News Detail
Loading, please wait...

INBX Latest Social Stream


Loading social stream, please wait...

View Full INBX Social Stream

Latest INBX News From Around the Web

Below are the latest news stories about INHIBRX INC that investors may wish to consider to help them evaluate INBX as an investment opportunity.

Inhibrx Announces Participation in Upcoming Investor Conference

Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming virtual investor conference:

Yahoo | November 18, 2022

Inhibrx (INBX) Down on Updated Data From Bone Cancer Study

Inhibrx (INBX) shares fall after it reports safety and efficacy data from phase I cohorts of a study evaluating its lead candidate INBRX-109 for chondrosarcoma.

Yahoo | November 18, 2022

Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate

Inhibrx Inc (NASDAQ: INBX) announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for chondrosarcoma, a rare type of cancer that usually begins in the bones. Inhibrx presented this dataset as of May 2022 at the Annual Connective Tissue Oncology Society Conference, which included matured data on the original chondrosarcoma cohort and initial data from an additional cohort of chondrosarcoma patients with the isocitrate dehydrogenase (IDH) mutation. Related:

Yahoo | November 16, 2022

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety data from the ongoing Phase 1 INBRX-109 expansion cohorts for the treatment of chondrosarcoma. Inhibrx presented this dataset as of May 2022 at the Annual Connective Tissue Oncology Society (CTOS) Conference today, which included matured data on the original chondrosarcoma cohort and initial data from an

Yahoo | November 16, 2022

Inhibrx Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Inhibrx ( NASDAQ:INBX ) Third Quarter 2022 Results Key Financial Results Net loss: US$35.3m (loss widened by 72% from...

Yahoo | November 9, 2022

Read More 'INBX' Stories Here

INBX Price Returns

1-mo -10.44%
3-mo 72.06%
6-mo 149.96%
1-year -28.72%
3-year N/A
5-year N/A
YTD -34.01%
2021 32.45%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7899 seconds.